LISBON, Oct. 19 (Xinhua) — On Tuesday (Oct. 18) Portuguese start-up Immunethep. The Paragon Novell (PNV) vaccine, the world’s first multiple bacterial vaccine, has been released. It will receive 2.5 million euros (approximately 93.7 million baht) of funding to advance clinical trials in humans.
Such trials will assess safety. immune stimulation and the initial efficacy of the Paragon Novel vaccine, which might receive 17.5 million euros (approximately 656 million baht) of global investment in the long term.
Previous reports have indicated that the Paragon Novell vaccine protects once morest five bacterial infections, including pneumococcus. (pneumococcus), which is the cause of pneumonia and called the product a revolution in vaccines.
Bruno Santos, co-founder and executive director of Immuntep It said the Paragon Novel vaccine will fight antibiotic-resistant bacteria linked to hospital-acquired infections. This creates serious global problems, and the company has negotiated clinical trials with investors.
